Mr. Schorno has more than 15 years of experience leading finance functions at innovative commercial-stage biotechnology companies, most recently as CFO and head of operations at 23andMe, a leading consumer genetics and research company.
“Dean joins the Rigel management team at an important crossroad as we transition to commercialization with the FDA approval and recent launch of TAVALISSE, an important new treatment option for adults with chronic immune thrombocytopenia, who have had an insufficient response to a previous treatment,” Raul Rodriguez, president and CEO of Rigel, said in a statement.
“We will rely on Dean’s leadership to guide our corporate finance function as well as related strategic and operational implementations as we launch our new product,” he added.
